,0
0,Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023
1,Incyte (INCY) Stock Plummets 29.6% Year to Date: Here's Why
2,Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
3,Data From Incyte’s Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)
4,Incyte (INCY) Posts Upbeat Data From Phase II Vitiligo Study
5,Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
6,New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura® (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients
7,Incyte and Mandy Moore Partner to Empower People with Atopic Dermatitis to Find Their Moments of Clarity
8,Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
9,Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil
